Buy Meropenem

The drug is indicated for the treatment (as monotherapy or in combination with other antimicrobial agents) of the following serious infections in children and adults caused by one or more pathogens susceptible to the drug:

• pneumonia (including hospital ones);
• abdominal infections;
• septicemia;
• meningitis;
• gynecological infections (such as endometritis and pelvic inflammatory disease);
• infections of the urinary system (pyelonephritis, pyelitis);
• infections of the skin and soft tissues (including erysipelas, impetigo, secondarily infected dermatoses);
• empiric therapy for suspected bacterial infection in adult patients with febrile episodes associated with neutropenia, as monotherapy or in combination with antiviral or antifungal drugs, aminoglycosides, cephalosporins, or semisynthetic penicillins.

The most common side effects are:

• diarrhea,
• nausea and vomiting,
• inflammation at the injection site,
• headache,
• rash,
• thrombocytosis,
• thrombophlebitis,
• increased activity of "hepatic" transaminases, alkaline phosphatase, lactate dehydrogenase and bilirubin concentration in blood serum.

 

Many of these side effects have been observed in the treatment of severely ill individuals already taking many medications, including vancomycin. There have been several reports of cases of severe hypokalemia.

Overdose

Symptoms: dizziness, headaches, paresthesia.

Treatment: symptomatic, with renal failure, hemodialysis is effective.

The main contraindication is hypersensitivity to the drug, as well as severe hypersensitivity (anaphylactic reactions, severe skin reactions) to any antibacterial agent that has a beta-lactam structure (i.e. to penicillins or cephalosporins).

Prohibited for use in children under 3 months.

Carefully

Simultaneous use with potentially nephrotoxic drugs. Patients with complaints from the gastrointestinal tract (diarrhea), especially those suffering from colitis.

Pregnancy and lactation

The clinical safety of Meronem during pregnancy has not been established. Experimental animal studies have not shown any adverse effects on the developing fetus. Meronem should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. In each case, the drug must be used under the direct supervision of a physician. Meropenem is found in the breast milk of animals at very low concentrations. Meronem should not be used during lactation (breastfeeding) unless the potential benefit justifies the potential risk to the baby.

It is used intravenously as a bolus for at least 5 minutes, or as an intravenous infusion over 15-30 minutes.

Adults

The dose and duration of therapy should be adjusted according to the type and severity of the infection and the condition of the patient. The following daily doses are recommended:

In the treatment of pneumonia, urinary tract infections, gynecological infections, infections of the skin and soft tissues - 500 mg intravenously every 8 hours.

In the treatment of nosocomial pneumonia, peritonitis, suspected bacterial infection in patients with symptoms of neutropenia, as well as septicemia - 1 g intravenously every 8 hours.

In the treatment of meningitis, the recommended dose is 2 g every 8 hours. The safety of using a dose of 2 g as a bolus injection has not been sufficiently studied.

Dose in adult patients with impaired renal function

In patients with creatinine clearance less than 51 ml / min, the dose should be reduced:

Creatinine clearance	Dose	Frequency of adm. (ml/min)
26-50	one dose unit (500mg, 1g, 2g)	every 12 hours
10-25	0.5 dose units	every 12 hours
<10	0.5 dose units	every 24 hours

Meropenem is eliminated by hemodialysis and hemofiltration. If long-term treatment with Meropenem is required, it is recommended that the drug (depending on the type and severity of the infection) be administered at the end of the hemodialysis procedure in order to restore effective plasma concentrations. At present, there are no data on the experience of using the drug Meropenem for administration to patients on peritoneal dialysis.

Dosage in adult patients with impaired liver function. In patients with hepatic insufficiency, there is no need for dose adjustment.

Elderly patients

Elderly patients with normal renal function or creatinine clearance greater than 50 ml/min do not require dose adjustment.

Children

For children aged 3 months to 12 years, the recommended dose for intravenous administration is 10-20 mg / kg every 8 hours, depending on the type and severity of the infection, the sensitivity of the pathogen and the condition of the patient. In children weighing more than 50 kg, doses should be used for adults.

For meningitis, the recommended dose is 40 mg/kg every 8 hours. The safety of taking a dose of 40 mg / kg as a bolus injection has not been sufficiently studied. There is no experience with the drug in children with impaired liver and kidney function.

Administration method

Meropenem for intravenous use can be administered as an intravenous bolus injection over at least 5 minutes, or as an intravenous infusion over 15-30 minutes; appropriate infusion fluids should be used for dilution. To prepare a solution for intravenous bolus injection, Meropenem should be dissolved with sterile water for injection (5 ml per 250 mg of meropenem), while the concentration of the solution is 50 mg / ml. To prepare a solution for intravenous infusion, Meropenem should be dissolve with 0.9% sodium chloride solution for infusion or 5% dextrose (glucose) solution for infusion, while the concentration of the solution should be from 1 to 20 mg / ml. The prepared solution should be administered immediately after preparation. Meropenem should not be mixed or added to other drugs. When diluting Meropenem, the standard antiseptic regimen should be observed.

Meronem should be used with caution in patients with a history of hypersensitivity to carbapenems, penicillins, or other beta-lactam antibiotics.

The use of Meronem in patients with liver disease should be carefully monitored for transaminase and bilirubin levels.

As with other antibiotics, non-susceptible microorganisms may predominate, and therefore constant monitoring of each patient is necessary.

Use in infections caused by methicillin-resistant staphylococcus aureus is not recommended.

Pseudomembranous colitis occurs with virtually all antibiotics and can range in intensity from mild to life-threatening. Therefore, antibiotics should be used with caution in individuals with gastrointestinal complaints, especially in patients with colitis. It is important to keep in mind the diagnosis of "pseudomembranous colitis" in case of diarrhea while taking an antibiotic. Although studies have shown that a toxin produced by Clostridium difficile is one of the main causes of antibiotic-associated colitis, other causes must be considered.

As with other antibiotics, regular susceptibility testing is recommended when meropenem is used as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa lower respiratory tract infection.

Co-administration of Meronem with potentially nephrotoxic drugs should be considered with caution.

You can buy Meropenem from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Meropenem without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Meropenem our website without prescription! 

Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem, causing an increase in its half-life and plasma concentrations. Since the efficacy and duration of action of Meronem without probenecid are adequate, the co-administration of probenecid with Meronem is not recommended. The possible effect of Meronem on the metabolism and protein binding of other drugs has not been studied. However, given the low binding of meropenem to plasma proteins (about 2%), it can be assumed that there should be no interaction with other drugs. Meronem was administered while taking other drugs, and no adverse pharmacological interactions were noted. However, there are no specific data on possible drug interactions.